pubrio
PolTREG S.A.

PolTREG S.A.

Poland · Biotechnology Research

Research

Pharmaceuticals

Biotechnology

Healthcare

Biotechnology Research

PolTREG was established as a spin-off from the Medical University of Gdańsk in order to develop and commercialize patented TREG method. PolTREG is the most advanced company in TREGS cellular therapies worldwide, breakthrough therapies for type 1 diabetes (T1D) and multiple sclerosis (MS). PolTREG has very promising results regarding the safety and efficacy of TREGS therapy (completed phase I/II clinical trials in T1D and phase I in MS), ready for the next phase of trials. The company is after EMA Scientific Advice procedure.

Company Insights
Company Overview

2015

Founded

Biotechnology Research

Industry

Poland

Location

12,267,370

Ranking

40 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding PolTREG S.A.

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​